Blueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-Targeted Therapeutics
Blueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-Targeted Therapeutics
-- Dr. Mariana Castells, M.D., Ph.D., a renowned researcher and clinical expert in mast cell diseases, will join members of Blueprint Medicines' management team to provide a perspective on the mast cell as a promising target for treating allergic and inflammatory disease on April 25, 2024, at 10:00 a.m. ET --
— 美國東部時間2024年4月25日上午10點，肥大細胞病的著名研究員和臨床專家Mariana Castells博士將與Blueprint Medicines管理團隊成員一起，就肥大細胞作爲治療過敏和炎性疾病的有前景靶標發表觀點——
-- First in a series of planned webcasts hosted by Blueprint to highlight evolving science around R&D and pipeline strategy --
——Blueprint計劃舉辦的一系列網絡直播中的第一場，旨在重點介紹圍繞研發和管道戰略不斷髮展的科學知識——
CAMBRIDGE, Mass., April 11, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced it will launch a webcast series to provide scientific perspectives and showcase the company's research and development strategy. The first event in this series will feature Dr. Mariana Castells, a renowned leader in mast cell research and clinical expert in allergic/inflammatory diseases, as a guest speaker.
馬薩諸塞州劍橋，2024年4月11日 /PRNewswire/ — Blueprint Medicines Corporation（納斯達克股票代碼：BPMC）今天宣佈將推出網絡直播系列，以提供科學視角並展示該公司的研發戰略。該系列的第一場活動將邀請肥大細胞研究領域的知名領導者和過敏/炎症性疾病臨床專家Mariana Castells博士作爲演講嘉賓。
Mast cells are increasingly implicated in the pathogenesis of a wide range of allergic and inflammatory conditions, leading to an acceleration in research into mast cell biology. This webcast will focus on the biology of mast cells, including their essential role as drivers of and contributors to inflammatory responses, their core involvement in biological pathways relevant to an array of allergic and inflammatory diseases, and Blueprint's approach to modulating mast cells and building a pipeline in allergic and inflammatory disease. The webcast will include a presentation and live Q&A.
肥大細胞越來越多地參與各種過敏和炎症性疾病的發病機制，從而加速了肥大細胞生物學的研究。本次網絡直播將重點關注肥大細胞的生物學，包括它們作爲炎症反應驅動因素和促成者的重要作用、它們在與一系列過敏和炎性疾病相關的生物通路中的核心作用，以及Blueprint調節肥大細胞和建立過敏和炎性疾病管道的方法。網絡直播將包括演示和現場問答。
Title: The powerful mast cell: a promising target for treating allergic and inflammatory diseases
標題： 強大的肥大細胞：治療過敏和炎性疾病的有希望的靶標
Date: Thursday, April 25, 2024
日期： 2024年4月25日，星期四
Time: 10:00 a.m. ET
時間： 美國東部時間上午 10:00
Presenters:
主持人：
Guest speaker
演講嘉賓
- Mariana Castells, M.D., Ph.D., Director, Mastocytosis Center at Brigham and Women's Hospital
- 瑪麗安娜·卡斯特爾斯，醫學博士，布里格姆婦女醫院肥大細胞增多症中心主任
Blueprint Medicines speakers
藍圖藥品揚聲器
- Fouad Namouni, M.D., President, Research & Development
- Becker Hewes, M.D., Chief Medical Officer
- Percy H. Carter, Ph.D., MBA, Chief Scientific Officer
- 福阿德·納穆尼，醫學博士，研發總裁
- Becker Hewes，醫學博士，首席醫療官
- Percy H. Carter，博士，工商管理碩士，首席科學官
To access the live webcast, please dial 833-470-1428 (domestic) or 404-975-4839 (international) and refer to conference ID 814168. A live webcast of the event will be available under "Events and Presentations" in the Investors & Media section of the Blueprint Medicines website at The archived webcast will be available on Blueprint Medicines' website approximately two hours after each event and will be available thereafter.
要觀看網絡直播，請撥打833-470-1428（國內）或404-975-4839（國際），並參考會議編號814168。該活動的網絡直播將在Blueprint Medicines網站的 “投資者與媒體” 部分的 “活動和演講” 下提供。存檔的網絡直播將在每次活動結束約兩小時後在Blueprint Medicines的網站上播出，之後將播出。
Blueprint plans to host the next webcast in the series in the second half of 2024.
藍圖計劃在2024年下半年舉辦該系列的下一次網絡直播。
About Blueprint Medicines
關於《藍圖藥品》
Blueprint Medicines is a fully integrated, commercial-stage, global biopharmaceutical company that invents life-changing medicines in two core, strategic areas of allergy/inflammation and oncology/hematology. We pursue discovery, development, and commercialization of therapies that potently and selectively target known drivers of disease, with focused investment in therapeutic areas where we can leverage our core expertise and business infrastructure to bring scale to our science. We are bringing AYVAKIT/AYVAKYT (avapritinib) to people living with systemic mastocytosis (SM) in the U.S. and Europe. Additionally, we have a pipeline of research and development programs that range from early science to advanced clinical trials in mast cell-mediated diseases, including SM and chronic urticaria, and oncology including breast cancer, and other solid tumors vulnerable to CDK2 inhibition. For more information, visit and follow us on X (formerly Twitter; @BlueprintMeds) and LinkedIn.
Blueprint Medicines是一家完全整合的、處於商業階段的全球生物製藥公司，在過敏/炎症和腫瘤學/血液學這兩個核心戰略領域發明了改變生活的藥物。我們致力於發現、開發和商業化能夠有效和有選擇地針對已知疾病驅動因素的療法，重點投資於治療領域，在這些領域我們可以利用我們的核心專業知識和業務基礎設施來擴大我們的科學規模。我們正在爲美國和歐洲的系統性肥大細胞增多症（SM）患者提供AYVAKIT/AYVAKYT（阿伐替尼）。此外，我們還有一系列研發項目，從早期科學到高級臨床試驗，涉及肥大細胞介導的疾病，包括SM和慢性蕁麻疹，以及包括乳腺癌在內的腫瘤學以及其他易受CDK2抑制的實體瘤。欲了解更多信息，請在 X（前身爲 Twitter；@BlueprintMeds）和 LinkedIn 上訪問並關注我們。
SOURCE Blueprint Medicines Corporation
來源 Blueprint
譯文內容由第三人軟體翻譯。